


AMENDMENTS TO THE CLAIMS:

Claims 1-4 (canceled)

5. (New) A 3-deoxy-D-myo-inositol analog having the formula (I):



wherein X is O or CH₂; R¹ and R² are individually, (C₁ -C₂₅) alkyl, (C₆ -C₁₀) aryl, (C₃ -C₈) cycloalkyl, (C₂ -C₂₂) alkenyl, (C₅ -C₈) cycloalkenyl, (C₇ -C₃₂) aralkyl, (C₇ -C₃₂) alkylaryl, (C₉ -C₃₂) aralkenyl, (C₉ -C₃₂) alkenylaryl or C(O)R³; and R³ is (C₁ -C₂₅) alkyl, (C₆ -C₁₀) aryl, (C₃ -C₈) cycloalkyl, (C₂ -C₂₂) alkenyl, (C₅ -C₈) cycloalkenyl, (C₇ -C₃₂) aralkyl, (C₇ -C₃₂) alkylaryl, (C₉ -C₃₂) aralkenyl or (C₉ -C₃₂) alkenylaryl, with the proviso that when X is O, R³ is not (C₁₅) alkyl; R⁴ and R⁵ are individually hydrogen or a phosphate group; or when R⁴ or R⁵ is not hydrogen, a pharmaceutically acceptable salt thereof.

6. (New) The 3-deoxy-D-myo-inositol analog of claim 5, wherein X is O.

7. (New) The 3-deoxy-D-myo-inositol analog of claim 6, wherein R¹ is methyl.

8. (New) The 3-deoxy-D-myo-inositol analog of claim 6, wherein R² is octadecyl.

9. (New) The 3-deoxy-D-myo-inositol analog of claim 5, wherein X is CH₂.

10. (New) The 3-deoxy-D-myo-inositol analog of claim 9, wherein O—R¹ and/or O—R² is palmitoyl.

11. (New) A method of inhibiting cell growth in a subject in need of such inhibition comprising administering to a subject an effective amount of a 3-deoxy-D-myo-inositol analog according to claim 5.

12. (New) The method of claim 11, wherein the compound is 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol.

13. (New) The method of claim 12, wherein 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol is administered to a subject in a daily dose of between 0.1 and 500 mg for each kilogram of the subject's weight.

14. (New) The method of claim 13, wherein 1-O-octadecyl-2-O-methyl-sn-glycero-3-phospho-1D-3-deoxy-myo-inositol is administered to a subject in a daily dose of about 50-100 mg for each kilogram of the subject's weight.

15. (New) The method of claim 11, wherein said compound inhibits PtdIns-3-kinase signaling.

16. (New) The method of claim 15, wherein inhibiting PtdIns-3-kinase signaling comprises inhibiting a src-homology 2 domain of a p85 regulatory subunit of PtdIns-3-kinase.

17. (New) The method of claim 11, wherein inhibiting cell growth comprises inhibiting the activity of a PH domain in a PH domain containing enzyme.

18. (New) The method of claim 17, wherein the PH domain activates the enzyme PKC- ζ and/or PKC- γ .

19. (New) The method of claim 11, wherein inhibiting cell growth comprises promoting the activity of a PH domain in a PH domain containing enzyme.

20. (New) The method of claim 19, wherein the PH domain activates the enzyme Akt.

21. (New) A pharmaceutical composition which comprises a therapeutically effective amount of a compound according to claim 5, and a pharmaceutically acceptable carrier.

22. (New) The composition of claim 21, which is suitable for administration via injection, orally, transdermally, intranasally, intraocularly, or rectally.